Alkermes plc reported third-quarter 2026 total revenues of $480.1 million, up from $394.2 million in the prior-year period, driven by proprietary product sales of $417.3 million. GAAP net income was $16.3 million, compared to $82.8 million previously, while adjusted EBITDA came in at $120.1 million. The nine-month results showed revenues of $1,369.1 million and a GAAP net loss of $49.7 million. The company reiterated its full-year 2026 financial expectations, including total revenue guidance of $1.73 billion to $1.84 billion. Alkermes is a global biopharmaceutical company developing innovative medicines in neuroscience.
